Role of the endocannabinoid system in depression and suicide
- PMID: 16919786
- DOI: 10.1016/j.tips.2006.08.006
Role of the endocannabinoid system in depression and suicide
Abstract
Depression is one of the most prevalent forms of neuropsychiatric disorder and is a major cause of suicide worldwide. The prefrontal cortex is a crucial brain region that is thought to be involved in the regulation of mood, aggression and/or impulsivity and decision making, which are altered in suicidality. Evidence of the role of the endocannabinoid (EC) system in the neurobiology of neuropsychiatric disorders is beginning to emerge. The behavioral effects of ECs are believed to be mediated through the central cannabinoid CB1 receptor. Alterations in the levels of ECs, and in the density and coupling efficacy of CB1 receptors, have been reported in the prefrontal cortex of depressed and alcoholic suicide victims. These findings support our hypothesis that altered EC function contributes to the pathophysiological aspects of suicidal behavior. Here, we provide a brief overview of the role of the EC system in alcoholism, depression and suicide, and discuss possible therapeutic interventions and directions for future research.
Similar articles
-
Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims.Biol Psychiatry. 2005 Mar 1;57(5):480-6. doi: 10.1016/j.biopsych.2004.11.033. Biol Psychiatry. 2005. PMID: 15737662
-
Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders.Life Sci. 2005 Aug 19;77(14):1569-83. doi: 10.1016/j.lfs.2005.05.041. Life Sci. 2005. PMID: 16005471 Review.
-
Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength.Int J Obes (Lond). 2006 Apr;30 Suppl 1:S19-23. doi: 10.1038/sj.ijo.0803273. Int J Obes (Lond). 2006. PMID: 16570100 Review.
-
Endocannabinoid system: An overview of its potential in current medical practice.Neuro Endocrinol Lett. 2009;30(2):153-79. Neuro Endocrinol Lett. 2009. PMID: 19675519 Review.
-
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.Int Rev Neurobiol. 2009;85:57-72. doi: 10.1016/S0074-7742(09)85005-8. Int Rev Neurobiol. 2009. PMID: 19607961
Cited by
-
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.Pharmaceuticals (Basel). 2010 Aug 26;3(9):2799-2820. doi: 10.3390/ph3092799. Pharmaceuticals (Basel). 2010. PMID: 27713377 Free PMC article. Review.
-
Cannabinoids and Sleep: Exploring Biological Mechanisms and Therapeutic Potentials.Int J Mol Sci. 2024 Mar 22;25(7):3603. doi: 10.3390/ijms25073603. Int J Mol Sci. 2024. PMID: 38612415 Free PMC article.
-
Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats.PLoS One. 2012;7(5):e36743. doi: 10.1371/journal.pone.0036743. Epub 2012 May 14. PLoS One. 2012. PMID: 22606285 Free PMC article.
-
How depression and antidepressant drugs affect endocannabinoid system?-review of clinical and preclinical studies.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4511-4536. doi: 10.1007/s00210-023-02938-z. Epub 2024 Jan 27. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38280009 Review.
-
Endocannabinoids and Precision Medicine for Mood Disorders and Suicide.Front Psychiatry. 2021 May 20;12:658433. doi: 10.3389/fpsyt.2021.658433. eCollection 2021. Front Psychiatry. 2021. PMID: 34093274 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical